In this issue:
CRISPR-boosted CAR T-cell immunotherapies
Tumour microenvironment after CAR T-cell therapy in B-ALL
Genetic determinants of CAR-T outcomes in LBCL
CAR-DLI ± lymphodepletion after allo-SCT in B-ALL
Point-of-care fresh CAR T-cells in B-cell precursor acute lymphoblastic leukaemia
Cilta-cel vs. ide-cel in R/R multiple myeloma
BCMA-targeted CAR T-cell therapy vs. BiTEs in R/R multiple myeloma
Healthcare resource utilisation with CAR T-cell therapy vs. ASCT in relapsed LBCL
CD19 CAR T-cell therapy in ICI-exposed/naïve PMBCL
CRS, bacteraemia & antibiotics after CAR T-cell therapy
Please login below to download this issue (PDF)